Latest News

TherapeuticsMD Enters Into Label Discussions for TX-001HR

BOCA RATON, Fla.–(BUSINESS WIRE)–TXMD entered label discussions with FDA for TX-001HR; PDUFA target action date for the completion of the FDA’s review of the NDA is Oct. 28, 2018

Related posts

Food neophobia may raise the risk of developing lifestyle diseases


Building performance evaluation: Balancing energy and indoor environmental quality in a UK school building


Study: Low-Dose Aspirin's Risks Outweigh Benefits


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy